Price
No data yet.
Social Signal Score
Revenue
$36.4K+797.88%Company Profile
- CEO
- Michael K. Korenko
- Sector
- Healthcare
- Industry
- Medical - Devices
- Employees
- 1
- Beta
- -0.71
- Country
- US
- Piotroski score
- 3 / 9 (Weak)
- Altman Z-score
- 61.40
Financials
Revenue
$36.4K+797.9%Net Income
$-830.2KEBITDA
$-654.2KFree Cash Flow
$-758.0KEPS (diluted)
$-0.00Shares Outstanding (diluted)
490.70M+19528.0%Operating Expenses
$492.9KCash & Debt
$2.34MReturn of Capital
$0.00Revenue by Segment (annual)
$2.1KQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $68.4K | $-3.07M | $-0.01 |
| 2024 | $28.0K | $-2.91M | $-0.01 |
| 2023 | $19.5K | $-2.90M | $-0.01 |
| 2022 | $36.5K | $-2.47M | $-0.01 |
| 2021 | $14.9K | $-2.53M | $-0.01 |
| 2020 | $7.0K | $-957.0K | $-0.00 |
| 2019 | $9.5K | $-1.61M | $-0.01 |
| 2018 | $0.00 | $-7.70M | $-0.14 |
| 2017 | $4.1K | $-6.42M | $-1.06 |
| 2016 | $8.1K | $-9.86M | $-3.67 |
| 2015 | $24.1K | $6.23M | $2.72 |
| 2014 | $24.1K | $-18.11M | $-45.38 |
| 2013 | $140.6K | $-3.47M | $-27.58 |
| 2012 | $248.0K | $-8.59M | $-90.77 |
Valuation
RDGLhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
30-82.35%Social Signal Score
Mentions (8)
- Newsglobenewswire.com·7d ago·Negative
Vivos Therapeutics Reports Progress in Material Cost Reductions and Revenue Growth Initiatives Vivos Management is Executing on Plan to Immediately Reduce Overhead by an Estimated $3.6 million Annually While Also Driving Top-Line Revenue Vivos Management is Executing on Plan to Immediately Reduce Overhead by an Estimated $3.6 million Annually While Also Driving Top-Line Revenue
View source ↗ - Newsglobenewswire.com·28d ago·Neutral
Vivos Therapeutics Announces Material Debt Reduction LITTLETON, Colo., Sept. 08, 2026 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. ("Vivos" or "the Company") (Nasdaq: VVOS), a medical device and healthcare services company focused on developing and commercializing diagnostic and treatment methods for patients with obstructive sleep apnea ("OSA") and other health conditions related to breathing and sleep disorders, today announced that on August 31, 2026, Vivos entered into twelve exchange agreem
View source ↗ - Newsnewsfilecorp.com·35d ago·Positive
Vivos Therapeutics to Present at the 2026 Moody Capital Solutions Disruptive Growth & Life Sciences Conference Littleton, Colorado--(Newsfile Corp. - September 1, 2026) - Vivos Therapeutics, Inc. (NASDAQ: VVOS) ("Vivos" or the "Company"), a leading medical technology and healthcare services company focused on the diagnosis and treatment of obstructive sleep apnea (OSA) and related breathing and sleep disorders, today announced that Founder and Chief Executive Officer R. Kirk Huntsman will presen
View source ↗ - Newsglobenewswire.com·39d ago·Positive
Vivos Therapeutics and South Palm Cardiovascular Associates Sign Definitive Agreements to Launch Regional Sleep Testing and Treatment Center LITTLETON, Colo., Aug. 28, 2026 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. ("Vivos" or "the Company") (Nasdaq: VVOS), a leading medical device and healthcare services company focused on developing and commercializing innovative diagnostic and treatment methods for patients suffering from obstructive sleep apnea ("OSA") and other health conditions related
View source ↗ - Newsglobenewswire.com·42d ago·Neutral
Vivos Therapeutics Reports Record New Patient Referrals at its Nevada Sleep & Airway Medicine Centers LITTLETON, Colo., Aug. 25, 2026 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“Vivos” or “the Company”) (Nasdaq: VVOS), a leading medical device and healthcare services company focused on developing and commercializing innovative diagnostic and treatment modalities for patients suffering from obstructive sleep apnea (“OSA”) and other sleep disorders, today announced that new OSA patient referral
View source ↗ - Newsglobenewswire.com·49d ago·Negative
…nd Authorization from India's Nuclear Regulatory Authority for International Manufacturing Center Kennewick, WA, Aug. 18, 2026 (GLOBE NEWSWIRE) -- Vivos Inc. (OTCQB: RDGL), a medical device company pioneering Precision Radionuclide Therapy™ (PRnT) for the treatment of cancerous tumors, today announced two significant operational milestones: the commencement of IsoPet® shipments from its new in-house U.S. production facility, and the receipt of authorization from The Atomic Energy Regulatory Boar…
View source ↗ - Newsglobenewswire.com·52d ago·Positive
Vivos Therapeutics Reports Second Quarter 2026 Financial Results and Provides Operational Update Quarter highlighted by steadily increasing patient demand for Vivos' differentiated array of highly effective OSA treatments Management to Host Conference Call today at 5:00 pm ET LITTLETON, Colo., Aug. 14, 2026 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“Vivos” or the “Company'') (NASDAQ: VVOS), a leading medical device and healthcare services company focused on developing and commercializing inn
View source ↗ - Newsglobenewswire.com·53d ago·Positive
Vivos Therapeutics Schedules Release of Second Quarter 2026 Financial Results and Conference Call LITTLETON, Colo., Aug. 14, 2026 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“Vivos” or the “Company'') (NASDAQ: VVOS), a leading medical device and healthcare services company focused on developing and commercializing innovative diagnostic and treatment modalities for patients suffering from obstructive sleep apnea (“OSA”) and other sleep related breathing disorders, announced it plans to release
View source ↗
Insider trading
Open-market buys and sells by RDGL officers and directors.
- Bought
- $325k
- Sold
- $25k
39 trades
11 trades
- Korenko Michael Kbought
- Weeks Brad Allanbought
- Weeks Brad Allanbought
- Korenko Michael Kbought
- Weeks Brad Allanbought
- Weeks Brad Allanbought
- Korenko Michael Kbought
- Weeks Brad Allanbought
50 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in RDGL.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.